Post by
piduks on Jun 28, 2024 7:32pm
Why the CEO is BIG risk to LABS
Large pharmaceutical companies in the United States are already FDA approved and if they have Canadian subsidiary operations those are approved by Health Canada. In Canada cannabinoids are legal at the Federal level be it pharmaceutical or recreational.
The recent rescheduling of Cannabis in the U.S. from the strickest classification of Schedule 3 (has pharmaceutical applications) vastly changes the landscape for Medipharm Labs.
So to be blunt and frank, who the f""K needs Medipharm Labs? Their DEL for cananbinoids is growing less valuable by the minute.
And you think the CEO has done a good job? Get your ostrich heads out of the sand.
Comment by
alleyesonme on Jun 28, 2024 8:42pm
https://businessofcannabis.com/us-reschedule-cannabis-drug-policy-opportunities-industry/